Clinical trial
Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot…
NCT00004248 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00004248 |
|---|---|
| Title | Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery |
| Official title | A Low Dose Schedule of Adriamycin and Protracted Infusion of Recombinant Interleukin-2: A Phase II Study of Immunotherapy in Unresectable Hepatocellular Carcinoma |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Biological, Drug |
| Interventions | aldesleukin, doxorubicin hydrochloride |
| Enrollment | 24 |
| Start date | Jul 1, 1999 |
| Primary completion | Jun 1, 2000 |
| Completion | May 1, 2001 |
| First posted | Mar 31, 2004 |
| Last update posted | Mar 7, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: